TY  - GEN
AU  - Kazantseva, Liliya
AU  - Becerra, José
AU  - Santos-Ruiz, Leonor
PY  - 2021
DO  - 10.1007/s43440-021-00324-1
SN  - 1734-1140
UR  - http://hdl.handle.net/20.500.12105/18445
AB  - Background: Doxorubicin is the chemotherapeutic drug of choice in osteosarcoma treatment, but its cumulative administration causes dilated cardiomyopathy. Combination therapy represents a potential strategy to reduce the therapeutic dosage of the...
LA  - eng
PB  - Springer
KW  - Osteosarcoma
KW  - Doxorubicin
KW  - Oridonin
KW  - Synergism
KW  - Combination therapy
KW  - Cardioprotection
KW  - Doxorrubicina
KW  - Sinergismo farmacológico
KW  - Quimioterapia combinada
KW  - Diterpenes, Kaurane
KW  - Osteosarcoma
KW  - Doxorubicin
KW  - Drug Synergism
KW  - Combined Modality Therapy
KW  - Isodon
KW  - Reactive Oxygen Species
KW  - Annexin A5
KW  - Biological Products
KW  - Flow Cytometry
KW  - Plants, Medicinal
KW  - Fluorescence
KW  - Cardiomyopathy, Dilated
KW  - Xanthenes
KW  - Apoptosis
KW  - Doxorubicin
KW  - Cell Death
KW  - Blotting, Western
KW  - Fluorescent Antibody Technique
KW  - Mitochondria
KW  - Software
TI  - Oridonin enhances antitumor effects of doxorubicin in human osteosarcoma cells
TY  - research article
ER  -